The rewarding/reinforcing effects of cocaine are produced by blocking reuptake of dopamine by the dopamine transporter (DAT). The DAT gene is expressed in dopaminergic neurons of the ventral midbrain, and serves as the only currently-available marker expressed almost exclusively by these cells. During this FY, we have completed sequencing of the human DAT gene of fifteen exons and fourteen introns with the exception of a highly polymorphic region whose position has not been accurately determined. We have characterized additional intron specific sequences and found one to be polymorphic in intron 8. We have identified new alleles at the genetic marker D5S678, and allele frequencies at this site in caucasian and african-americans. The wide distribution of mRNA expression of the new gene found by sequence match to various EST clones was determined. The 5'-end of this gene has not been mapped successfully and may be in close enough proximity to the DAT VNTR to be a candidate for the recent associations of the VNTR to cocaine-induced paranoia and attention deficit/ hyperactivity disorder. We have confirmed in 297 individuals that linkage disequilibrium values are very low for the VNTR marker in exon 15 and the TaqI RFLP in intron 3, which suggests that a significant amount of recombination has occurred within this gene since the origins of humans. A region within intron 14 of the DAT gene has been successfully cloned and sequenced. This region was not present in several genomic libraries and even proved difficult to clone from PCR fragments. The probable cause of the difficulty was evident from the presence of a homopolymeric run of 17 adenines flanked by a direct repeat of approximately 100 nucleotides, both of which could be unstable sequences in bacteria. This work strengthens the genetic power to detect the role of DAT in substance abuse and other neuropsychiatric disorders. Studies of DAT knockout transgenic mice completed during this FY reveal interesting differences in cocaine reward and locomotion.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000160-03
Application #
6161704
Study Section
Special Emphasis Panel (MN)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Yamashita, Motoyasu; Fukushima, Setsu; Shen, Hao-wei et al. (2006) Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31:2132-9
Drgon, Tomas; Lin, Zhicheng; Wang, Gene-Jack et al. (2006) Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 26:875-89
Lin, Zhicheng; Walther, Donna; Yu, Xiao-Ying et al. (2005) SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 14:1393-404
Liu, Qing-Rong; Zhang, Ping-Wu; Lin, Zhicheng et al. (2004) GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. Biochem J 377:171-81
Uhl, George R (2004) Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic process. Neuropharmacology 47 Suppl 1:140-7
Radzius, Aleksandras; Gallo, Joseph; Gorelick, David et al. (2004) Nicotine dependence criteria of the DIS and DSM-III-R: a factor analysis. Nicotine Tob Res 6:303-8
Lin, Zhicheng; Zhang, Ping-Wu; Zhu, Xuguang et al. (2003) Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 278:20162-70
Uhl, George R (2003) Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 18 Suppl 7:S71-80
Uhl, George R; Lin, Zhicheng (2003) The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol 479:71-82
Hall, F Scott; Sora, I; Uhl, G R (2003) Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 28:620-8

Showing the most recent 10 out of 14 publications